|
Books > Business & Economics > Industry & industrial studies > Manufacturing industries > Pharmaceutical industries
Technological innovations have become the impetus for continuous
developments in medical research. With the assistance of new
technologies, effective drug delivery techniques have been improved
for optimal patient care. Recent Advances in Drug Delivery
Technology is a pivotal reference source for the latest scholarly
research on the application of pharmaceutical technology to
optimize techniques for drug delivery in patients. Focusing on
novel approaches in pharmaceutical science, this book is ideally
designed for medical practitioners, upper-level students,
scientists, and researchers.
Every year the average number of prescriptions purchased by
Americans increases, as do healthcare expenditures, which are
projected to reach one-fifth of the U.S. gross domestic product by
2020. In "Drugs for Life," Joseph Dumit considers how our
burgeoning consumption of medicine and cost of healthcare not only
came to be, but also came to be taken for granted. For several
years, Dumit attended pharmaceutical industry conferences; spoke
with marketers, researchers, doctors, and patients; and surveyed
the industry's literature regarding strategies to expand markets
for prescription drugs. He concluded that underlying the continual
growth in medications, disease categories, costs, and insecurity is
a relatively new perception of ourselves as inherently ill and in
need of chronic treatment. This perception is based on clinical
trials that we have largely outsourced to pharmaceutical companies.
Those companies in turn see clinical trials as investments and
measure the value of those investments by the size of the market
and profits that they will create. They only ask questions for
which the answer is more medicine. "Drugs for Life" challenges our
understanding of health, risks, facts, and clinical trials, the
very concepts used by pharmaceutical companies to grow markets to
the point where almost no one can imagine a life without
prescription drugs.
While systems biology and pharmacodynamics have evolved in
parallel, there are significant interrelationships that can enhance
drug discovery and enable optimized therapy for each patient.
Systems pharmacology is the relatively new discipline that is the
interface between these two methods. This book is the first to
cover the expertise from systems biology and pharmacodynamics
researchers, describing how systems pharmacology may be developed
and refined further to show practical applications in drug
development. There is a growing awareness that pharmaceutical
companies should reduce the high attrition in the pipeline due to
insufficient efficacy or toxicity found in proof-of-concept and/or
Phase II studies. Systems Pharmacology and Pharmacodynamics
discusses the framework for integrating information obtained from
understanding physiological/pathological pathways (normal body
function system vs. perturbed system due to disease) and
pharmacological targets in order to predict clinical efficacy and
adverse events through iterations between mathematical modeling and
experimentation.
Managing the Drug Discovery Process: How to Make It More Efficient
and Cost-Effective thoroughly examines the current state of
pharmaceutical research and development by providing
chemistry-based perspectives on biomedical research, drug hunting
and innovation. The book also considers the interplay of
stakeholders, consumers, and the drug firm with attendant factors,
including those that are technical, legal, economic, demographic,
political, social, ecological, and infrastructural. Since drug
research can be a high-risk, high-payoff industry, it is important
to researchers to effectively and strategically manage the drug
discovery process. This book takes a closer look at increasing
pre-approval costs for new drugs and examines not only why these
increases occur, but also how they can be overcome to ensure a
robust pharmacoeconomic future. Written in an engaging manner and
including memorable insights, this book is aimed at redirecting the
drug discovery process to make it more efficient and cost-effective
in order to achieve the goal of saving countless more lives through
science. A valuable and compelling resource, this is a must-read
for all students and researchers in academia and the pharmaceutical
industry.
This book is open access under a CC-BY license. The importance of
the pharmaceutical industry in Sub-Saharan Africa, its claim to
policy priority, is rooted in the vast unmet health needs of the
sub-continent. Making Medicines in Africa is a collective
endeavour, by a group of contributors with a strong African and
more broadly Southern presence, to find ways to link technological
development, investment and industrial growth in pharmaceuticals to
improve access to essential good quality medicines, as part of
moving towards universal access to competent health care in Africa.
The authors aim to shift the emphasis in international debate and
initiatives towards sustained Africa-based and African-led
initiatives to tackle this huge challenge. Without the
technological, industrial, intellectual, organisational and
research-related capabilities associated with competent
pharmaceutical production, and without policies that pull the
industrial sectors towards serving local health needs, the African
sub-continent cannot generate the resources to tackle its
populations' needs and demands. Research for this book has been
selected as one of the 20 best examples of the impact of UK
research on development. See
http://www.ukcds.org.uk/the-global-impact-of-uk-research for
further details.
The biohealthcare executive in upper-middle management confronts
leadership challenges unique to their industry: they manage highly
specialized knowledge workers and innovators, compete at the speed
of technology, work in a highly regulated environment where "free
speech" often does not apply due to patient safety and privacy
concerns, and increasingly are leading virtual teams who may be
located in different parts of the world. Practical leadership for
biopharmaceutical executives is a guide that strips away the theory
and meets head-on the practical leadership challenges these
executives face on a daily basis, and provides these "innovator
leaders" with the tools to lead effectively in the face of
technological complexity.
This volume provides information on how to select and screen plants
for their medicinal properties. It describes phytopharmacological
techniques for extracting and qualitatively and quantitatively
analyzing a plant's phytochemicals. After a detailed in vitro
investigation including nutritional and anti-nutritional analyses,
medicinal properties were tested with various in vivo models for
anti-inflammatory, analgesic, anti-pyretic, anticancer and
anti-diabetic properties, as well as wound healing,
neurodegenerative diseases, etc. Compound identification and
purification techniques include, among others, TLC and column
chromatography, as well as molecular docking with specific
proteins.
I am encouraged to see healthcare leaders looking beyond the ways
they have always done things in the past to implement innovative
solutions to curb the industry's skyrocketing costs, poor quality,
nursing shortages and employee dissatisfaction; all symptoms of
deeper problems inherent in the system itself. Today's forward
looking healthcare providers have realized the financial and moral
imperatives for improving quality and safety and eliminating waste
as strategies for responding to their pressing challenges. Lean
Healthcare (adapted from the Toyota Production System) is not just
for manufacturing or another short-term fix; it's a way to
transform an entire organization into a safe and high-quality,
high-performing healthcare delivery system. If implemented
properly, it can be the "how to" for managing change and creating
continuous improvement.
|
Cosmeceuticals
(Hardcover)
Y. Madhusudan Rao, Shayeda
|
R3,042
R2,435
Discovery Miles 24 350
Save R607 (20%)
|
Ships in 10 - 15 working days
|
|
This book provides an overview of the global pharmaceutical pricing
policies. Medicines use is increasing globally with the increase in
resistant microbes, emergence of new treatments, and because of
awareness among consumers. This has resulted in increased drug
expenditures globally. As the pharmaceutical market is expanding, a
variety of pharmaceutical pricing strategies and policies have been
employed by drug companies, state organizations and pharmaceutical
pricing authorities.
This book critically investigates the patent protection of
medication in light of the threats posed by HIV/AIDS, malaria and
tuberculosis epidemics to the citizens of countries in Sub-Saharan
Africa (hereinafter "SSA" or "Africa"). The book outlines the
systemic problems associated with the prevailing globalized patent
regime and the regime's inability to promote access to life-saving
medication at affordable prices in SSA. It argues that for
pharmaceutical patents to retain their relevance in SSA countries,
human development concepts must be integrated into global patent
law- and policy-making. An integrative approach implies developing
additional public health and human development
exceptions/limitations to the exercise of patent rights with the
goal of scaling up access to medication that can treat epidemics in
SSA. By drawing on multiple perspectives of laws, institutions,
practices, and politics, the book suggests that SSA countries adopt
an evidence-based approach to implementing global patent standards
in domestic jurisdictions. This evidence-based approach would
include mechanisms like local need assessments and the use of
empirical data to shape domestic patent law-making endeavors. The
approach also implies revising patent rules and policies with a
pro-poor and pro-health emphasis, so that medication will be more
affordable and accessible to the citizens of SSA countries. It also
suggests considering the opinions of individuals and pro-access
institutions in enacting crucial pieces of health-related statutes
in SSA countries. The approach in this book is sensitive to the
public health needs of the citizens affected by epidemics and to
the imperative of building local manufacturing facilities for
pharmaceutical research and development in SSA.
This book explains how government support and institutional set up
facilitated the evolution of the Indian pharmaceutical industry and
provides an economic analysis of firm strategies due to recent
policy changes. The book is useful for researchers interested in
understanding the transition of a lifeline sector for an emerging
economy like India. Students of public policy, health
administrators and health economists who are interested in the
functioning of the pharmaceutical sector that produces life saving
drugs in developing nations will find this book useful. The book
also provides good coverage on data envelopment analysis (DEA), a
useful technique for understanding productivity and efficiency. It
can provide guidance to the research students on the applicability
of DEA technique to address various research questions for
analysis. The book will be a valuable addition to libraries in
colleges of pharmacy and medicine as well as to all other academic
and research centers.
Our recent understanding of the cellular and molecular defects and
the regulation of the apoptotic signalling pathways has resulted in
rationally designed anticancer strategies and the development of
novel agents that regulates apoptosis. A comprehensive review of
all apoptotic-related anticancer therapies is not the purpose of
this book. However, in the volume of this book with 11 chapters, we
have described a number of novel apoptotic regulators that have
shown promising value and also great feasibility for cancer
treatment. These novel agents either occur naturally or are
chemically synthesized. While we are excited about the discovery
and development of these novel apoptotic regulators as potential
anticancer agents, a degree of caution should be always borne in
mind when interpreting the success of preclinical pro-apoptotic
candidates since potential problems inevitably lie ahead. These
problems usually include target specificity, unanticipated
toxicity, compound stability, formulation issues, pharmacokinetic
and pharmacodynamic profiles. Nevertheless, we believe that this
collection of 11 chapters by established leaders in the area of
apoptosis will be of great interest to not only academics working
in the field of cancer research and apoptosis but also
pharmaceutical and pharmacological industries that . We are looking
forward to the further development to push these potential agents
toward clinical stage.
|
|